AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1

References

• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
   PubMed Web of Science ®Google Scholar
• Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003;29(6):533–540.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–425.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer. 2010;116(5):1336–1343.
   PubMed Web of Science ®Google Scholar
• Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non–small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16(23):5873–5882.
   PubMed Web of Science ®Google Scholar
• Khalifa J, Amini A, Popat S, et al. International association for the study of lung cancer advanced radiation technology C. Brain metastases from NSCLC: radiation therapy in the era of targeted therapies. J Thorac Oncol. 1627-43;2016:11.
   Google Scholar
• Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82(2):282–287.
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77:556–560.
   PubMed Web of Science ®Google Scholar
• Ommori R, Park K, Miyagawa F, et al. Epidermal growth factor receptor (EGFR) inhibitory monoclonal antibodies and EGFR tyrosine kinase inhibitors have distinct effects on the keratinocyte innate immune response. Br J Dermatol. 2018;178(3):796.
   PubMed Web of Science ®Google Scholar
• Clark RRAMB, Mclaren A, Clark B. Real world experience of third line docetaxel ± nintedanib post-nivolumab for treatment of metastatic NSCLC in the West of Scotland. Lung Cancer. 2019;127:37–38.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Wang J, Cheng Z, et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system- penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem. 2015;58:8200–8215.
   PubMed Web of Science ®Google Scholar
• Yang Z, Guo Q, Wang Y, et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016;8(368):368ra172.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Kim DW, Cho BC, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, openlabel, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5:891–902.
   PubMed Web of Science ®Google Scholar
• Rafehi H, Orlowski C, Georgiadis GT, et al. 2011. Clonogenic assay: adherent cells. J Vis Exp. 49. DOI: 10.3791/2573.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Srdic-Rajic T, Konjevic G, et al. TNF-alpha induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011;239:115–122.
   PubMed Web of Science ®Google Scholar
• Lacombe F, Belloc F. Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Hematol Cell Ther. 1996;38(6):495–504.
   PubMedGoogle Scholar
• Jurisic V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteomics. 2020;17(9):663–674.
   PubMed Web of Science ®Google Scholar
• Ivashkevich A, Redon CE, Nakamura AJ, et al. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett. 2012;327(1–2):123–133.
   PubMed Web of Science ®Google Scholar
• Tang H, Duan C, Kuang Z, et al. Analyzing signaling pathways using antibody arrays. Methods Mol Biol. 2021;2237:225–236.
   PubMedGoogle Scholar
• Wang S, Zhang X, Wang G, et al. Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells. BMC Cancer. 2019;19(1):1160.
   PubMed Web of Science ®Google Scholar
• Yeom CJ, Chung JK, Kang JH, et al. Visualization of hypoxiainducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodidesymporter genes. J Nucl Med. 2008;49(9):1489–1497.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ren H, Dai B, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018;37(1):324.
   PubMed Web of Science ®Google Scholar
• Zhang SR, Zhu LC, Jiang YP, et al. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacol Sin. 2017;38:233–240.
   PubMed Web of Science ®Google Scholar
• Li X, Wang Y, Wang J, et al. Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer. Int J Cancer. 2018;143(1):212–224.
   PubMed Web of Science ®Google Scholar
• Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–5140.
   PubMed Web of Science ®Google Scholar
• Mahmood U, Kwok Y, Regine WF, et al. Whole-brain irradiation for patients with brain metastases: still the standard of care. Lancet Oncol. 2010;11(3):221–222. author reply 3.
   PubMed Web of Science ®Google Scholar
• Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31(7):895–902.
   PubMed Web of Science ®Google Scholar
• Chao D, Pang L, Shi Y, et al. AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop. Biochem Biophys Res Commun. 2019;509(2):535–540.
   PubMed Web of Science ®Google Scholar
• Yin W, Zhang K, Deng Q, et al. AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways. Bioengineered. 2021;12(1):8679–8689.
   Web of Science ®Google Scholar
• Wang Y, Liu S, Wei X, et al. Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report. Onco Targets Ther. 2018;11:4733–4738.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1–2):1–24.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109(Suppl):S121–31.
   PubMed Web of Science ®Google Scholar
• Liu L, Nam S, Tian Y, et al. 6-bromoindirubin-3’-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 2011;71:3972–3979.
   PubMed Web of Science ®Google Scholar
• Liao J, Xu T, Zheng JX, et al. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Int J Mol Med. 2013;32:79–84.
   PubMed Web of Science ®Google Scholar
• Tactacan CM, Phua YW, Liu L, et al. The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Mol Cancer. 2015;14(1):139.
   PubMed Web of Science ®Google Scholar
• Van Der Zee M, Sacchetti A, Cansoy M, et al. IL6/JAK1/STAT3 signaling blockade in endometrial cancer affects the ALDH hi /CD126+stem-like component and reduces tumor burden. Cancer Res. 2015;75(17):3608–3622.
   PubMed Web of Science ®Google Scholar
• Cao W, Liu Y, Zhang R, et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep. 2015;5(1):8477.
   PubMed Web of Science ®Google Scholar